EQS-Adhoc: Heidelberg Pharma Announces Changes to the Executive Management Board - Dr Dongzhou Jeffery Liu Appointed as Chairman of the Executive Board and Chief Executive Officer
|
EQS-Ad-hoc: Heidelberg Pharma AG / Key word(s): Personnel Ad hoc announcement Disclosure of inside information under Article 17 of Regulation (EU) No 596/2014 Heidelberg Pharma Announces Changes to the Executive Management Board - Dr Dongzhou Jeffery Liu Appointed as Chairman of the Executive Board and Chief Executive Officer Ladenburg, Germany, 24 November 2025 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that the Supervisory Board has revoked the appointment of Professor Andreas Pahl as member of the Executive Management Board and Chief Executive Officer, and has instead appointed Dr Dongzhou Jeffery Liu as Chairman of the Executive Management Board and new Chief Executive Officer, with immediate effect. Dr Liu has stepped down from his position as a member of the Supervisory Board of Heidelberg Pharma, with effect as of 23 December 2025. His permanent appointment as Chairman of the Executive Management Board and Chief Executive Officer will become effective as of 24 December 2025. For the transition period from today until 23 December 2025 he will be seconded as a deputy member to the Executive Management Board pursuant to section 105 (2) of the German Stock Corporation Act (Aktiengesetz) Dr Liu is Chief Scientific Officer (CSO) and President of Huadong Global Development at Huadong Medicine in Hangzhou, China. Prior to that he held various leading positions in the pharma industry in the US, including GlaxoSmithKline, Wyeth (now Pfizer) and Forest Labs (now Abbvie). His more than 25 years of industry experience include clinical and preclinical research & development of medicinal products, including ADC products. End of Inside Information Information and Explanation of the Issuer to this announcement: About Heidelberg Pharma Heidelberg Pharma is a biopharmaceutical company working on a new treatment approach in oncology and developing novel drugs based on its ADC technologies for the targeted and highly effective treatment of cancer. ADCs are antibody-drug conjugates that combine the specificity of antibodies with the efficacy of toxins to fight cancer. Selected antibodies are loaded with cytotoxic compounds, the so-called payloads, that are transported into diseased cells. Inside the cells, the toxins then unleash their effect and kill the diseased cells. Heidelberg Pharma is the first company to use the compound Amanitin from the green death cap mushroom in cancer therapy. The biological mechanism of action of the toxin represents a new therapeutic modality and is used as a compound in the Amanitin-based ADC technology, the so-called ATAC technology. The lead candidate HDP-101 (INN: pamlectabart tismanitin) is a BCMA ATAC in clinical development for multiple myeloma. The candidate has been granted Orphan Drug Designation and Fast Track Designation from the FDA. A second ATAC candidate, HDP-102 is in clinical development stage in Non-Hodgkin Lymphoma. HDP-103 against metastatic castration-resistant prostate cancer and HDP-104 targeting gastrointestinal tumors such as colorectal cancer have completed preclinical development. Heidelberg Pharma is open for partnering. The company is based in Ladenburg, Germany, and is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol HPHA. More information is available at www.heidelberg-pharma.com ATAC® is a registered trademark of Heidelberg Pharma Research GmbH.
This communication contains certain forward-looking statements relating to the Company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "will" "should" "future", "potential" or similar expressions or by a general discussion of the Company's strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial condition, performance, or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.
24-Nov-2025 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | Heidelberg Pharma AG |
| Gregor-Mendel-Str. 22 | |
| 68526 Ladenburg | |
| Germany | |
| Phone: | +49 (0)89 41 31 38 - 0 |
| Fax: | +49 (0)89 41 31 38 - 99 |
| E-mail: | investors@hdpharma.com |
| Internet: | www.heidelberg-pharma.com |
| ISIN: | DE000A11QVV0 |
| WKN: | A11QVV |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2235060 |
| End of Announcement | EQS News Service |
|
|
2235060 24-Nov-2025 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | 2026e | ||
| Sales1 | 8,49 | 1,75 | 18,51 | 9,86 | 6,85 | 8,20 | 0,00 | |
| EBITDA1,2 | -17,55 | -24,83 | -16,62 | -20,33 | -20,64 | 0,00 | 0,00 | |
| EBITDA-Margin3 | -206,71 | -1.418,86 | -89,79 | -206,19 | -301,31 | 0,00 | 0,00 | |
| EBIT1,4 | -18,28 | -25,63 | -17,18 | -21,21 | -20,67 | -30,00 | 0,00 | |
| EBIT-Margin5 | -215,31 | -1.464,57 | -92,82 | -215,11 | -301,75 | -365,85 | 0,00 | |
| Net Profit (Loss)1 | -18,37 | -26,14 | -19,70 | -20,35 | -19,38 | -32,00 | 0,00 | |
| Net-Margin6 | -216,37 | -1.493,71 | -106,43 | -206,39 | -282,92 | -390,24 | 0,00 | |
| Cashflow1,7 | -17,89 | -26,61 | -8,57 | -33,95 | -29,59 | 0,00 | 0,00 | |
| Earnings per share8 | -0,61 | -0,80 | -0,44 | -0,31 | -0,42 | -0,86 | -0,46 | |
| Dividend per share8 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: Baker Tilly
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| Heidelberg Pharma | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| A11QVV | DE000A11QVV0 | AG | 131,93 Mio € | 13.11.2006 | Kaufen | 8FXCFJCP+89 |
| PE 2027e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| -8,29 | 0,00 | 0,00 | -5,13 | 4,27 | -4,46 | 19,26 |
|
Dividend '2023 in € |
Dividend '2024 in € |
Dividend '2025e in € |
Div.-Yield '2025e in % |
| 0,00 | 0,00 | 0,00 | 0,00% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 23.06.2026 | 29.04.2026 | 15.07.2026 | 09.10.2025 | 26.03.2026 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| -2,83% | -18,73% | +13,71% | +17,99% | -79,57% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.
Contact
